

Page 001 to/à Page 006

Withheld pursuant to/removed as

s.21

Page 007 to/à Page 009

Withheld pursuant to/removed as

s.16;s.21

Page 010 to/à Page 037

Withheld pursuant to/removed as

s.21

Page 038 to/à Page 040

Withheld pursuant to/removed as

s.22;s.21;s.13

Page 041

Withheld pursuant to/removed as

s.13

# Recombinant Factor VIII Transitioning UPDATE

DECEMBER 2016

Copyright

vices site to another to avoid discards of unused prod-

Your questions and feedback can be sent to  
[Jennifer.TDavis@blood.ca](mailto:Jennifer.TDavis@blood.ca)



**rFVIII Inventory Update (Data current as of 29 November 2016)**

Copyright

Page 043

Withheld pursuant to/removed as

s.21

Page 044 to/à Page 045

Withheld pursuant to/removed as

s.22;s.21



Page 046 to/à Page 047

Withheld pursuant to/removed as

s.21

# **Fractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning**

## **Summary of product changes**

Copyright

Page 049 to/à Page 055

Withheld pursuant to/removed as

Copyright



Canadian Blood Services  
Société canadienne du sang

Head Office / Siège social  
1800 Alta Vista  
Ottawa, ON K1G 4J5  
T 613.739.2300 F 613.731.1411  
[www.blood.ca](http://www.blood.ca) [www.sang.ca](http://www.sang.ca)

---

**INFORMATION ONLY**

Plasma Protein Products Request for Proposal Results-Update

Customer Letter # 2017-46

---

Copyright

# **Fractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning**

## **Summary of product changes**

Copyright

Page 058 to/à Page 064

Withheld pursuant to/removed as

Copyright

# Plasma Protein Products Transition

December 2017

NEWS

Copyright

CHANGES



Canadian Blood Services  
*it's in you to give*

## **New products and product support:**

Shire 1-888-999-0287

Novo Nordisk 1-800-465-4334

# Plasma Protein Products Transition

January 2018

NEWS

CHANGES

Copyright

found at [www.blood.ca](http://www.blood.ca).



Canadian Blood Services  
*it's in you to give*

**New products and product support:**

Hizentra CARE	1-888-490-4105
Shire	1-888-999-0287
Novo Nordisk	1-800-465-4334



Page 067 to/à Page 068

Withheld pursuant to/removed as

Copyright



# Canadian Blood Services and BC&Y Hospitals Communication Forum

## Agenda

09-June- 2016 13:00 – 16:00hr

**Location Information:** Canadian Blood Services (CBS)  
4750 Oak St. Vancouver BC in the Yukon Room

Copyright

[

-

-

-

-

Page 070 to/à Page 104

Withheld pursuant to/removed as

Copyright

# Plasma Protein Products Transition

December 2017

NEWS

CHANGES

Copyright

**New products and product support:**

Shire 1-888-999-0287

Novo Nordisk 1-800-465-4334

Page 106 to/à Page 141

Withheld pursuant to/removal as

Copyright

# CBS Distribution News and Updates



Page 143 to/à Page 152

Withheld pursuant to/removed as

Copyright

# Transfusion Issues Education Day 2018

## Vancouver Island Sydney



**October 25, 2018.**

Please start sharing the date now.



# **BCSLS Annual Congress**

## **October 26-28, 2018**

### **Sidney BC, The Mary Winspear Centre**



Page 155 to/à Page 156

Withheld pursuant to/removed as

Copyright

<http://www.transfusion.ca/Events/2018-ISBT-International-Congress-Toronto>

ISBT

35th International Congress of the ISBT  
35<sup>e</sup> congrès international de l'ISBT  
June 2 – June 6, 2018 / Du 2 juin au 6 juin, 2018  
Toronto, Canada

In conjunction with the  
annual conference of the CSTM

Conjointement avec  
le congrès annuel de la SCMT



Page 158 to/à Page 163

Withheld pursuant to/removed as

Copyright

Page 164 to/à Page 182

Withheld pursuant to/removed as

s.21

---

**INFORMATION ONLY**

Plasma Protein Products Request for Proposal Results  
Customer Letter # 2017-42

Copyright

Page 184 to/à Page 185

Withheld pursuant to/removed as

Copyright

# Plasma Protein Products Transition

December 2017

NEWS

CHANGES

Copyright



Canadian Blood Services  
*it's in you to give*

#### New products and product support:

Shire	1-888-999-0287
Novo Nordisk	1-800-465-4334



## Leong, Katherine HLTH:EX

---

**From:** Irena Gordon <Irena.Gordon@blood.ca>  
**Sent:** Tuesday, June 12, 2018 1:31 PM  
**Cc:** Judy Hrytzak; O'Reilly, Clare; Cynthia Calinisan; Catherine Frost; Rosinski, Kristin [VA]; Lhevinne Ciurcovich; McMahon, Sarah; Ed Yee; Davidson, Heather A HLTH:EX; Manfredi, Sarah; Annie Ho  
**Subject:** Hospital Communication Forum Invitation  
**Attachments:** June 2018 Agenda Communication Forum.doc; June 2018 Power Point.pptx

Hi Everyone,

Attached are the following:

1. Updated Agenda
2. First Power point slide deck

Other slide decks will follow as received.

Irena

Best Regards,

**Irena Gordon**

Hospital Liaison Specialist

Canadian Blood Services, BC & Yukon

T: 604-707-3516 C: 604-787-1675 F: 606-707-3484

[Irena.gordon@blood.ca](mailto:Irena.gordon@blood.ca)



Call 1-888-2-DONATE (1-888-236-6283)



## Canadian Blood Services and BC&Y Hospitals Communication Forum Agenda

**June 14, 2018 13:00 – 16:00hr**

**Location Information:** Canadian Blood Services (CBS)  
4750 Oak St. Vancouver BC in the Fraser Room.

Copyright

[

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Page 189 to/à Page 228

Withheld pursuant to/removed as

Copyright

## Leong, Katherine HLTH:EX

---

**From:** Janet Unrau <janet.unrau@blood.ca>  
**Sent:** Monday, November 20, 2017 9:48 AM  
**To:** Andrew Shih; Brian Berry; Christorina Taruc; Darlene Mueller; XT:HLTH Gouthro, Daryl; Dr Doug Morrison ; Dr. Karen L. Dallas ; Kamran Azar; Kate Chipperfield ; Kristine Roland; Mark Bigham; Maureen Wyatt; Nick Au; Robert Coupland; Rodrigo Onell ; Sarah Oxley ; Shelley F; Tanya Petraszko; Victor Meneghetti; Vowles, Wendy M HLTH:EX  
**Subject:** Notifying Clinicians of the New Plasma Protein Products being Introduced and New Percentages of Products Available  
**Attachments:** CL 2017-42.pdf  
**Importance:** High

Hello;

The attached Customer Letter announced the results of the Plasma Protein Products Request for Proposal Results.

This Customer Letter is distributed via the public website [www.blood.ca](http://www.blood.ca) and to the physicians who have requested to be on the CBS email lists or who are Medical Directors of Hospital TML .

I realize that not all physicians want to receive all of the CBS Customer Letters but this letter will be of importance to a number of clinicians.

This email is to remind you to share this letter with clinicians within your health authority who you expect will be impacted by these RFP results .

Today I will be sending you an invitation to a t/con on Friday Nov 24 around noon to discuss the RFP results with CBS Head Office Peter Saunders .

This would be a good opportunity to provide any feedback or questions you receive from clinicians whose practice will be impacted by the change in PPP available .

Thank you for your attention to this important issue.

Best regards;  
Janet Unrau  
Hospital Liaison Specialist  
Canadian Blood Services BC&Yukon  
T: 604-707-3516 C: 604-787-1675 F: 604-707-3484



call 1-888-2-DONATE (1-888-236-6283)

---

**INFORMATION ONLY**

Plasma Protein Products Request for Proposal Results  
Customer Letter # 2017-42

---

Copyright

Page 231 to/à Page 232

Withheld pursuant to/removed as

Copyright

## Leong, Katherine HLTH:EX

---

**From:** Peter Saunders <peter.saunders@blood.ca>  
**Sent:** Tuesday, September 20, 2016 1:19 PM  
**To:** Vowles, Wendy M HLTH:EX; Leong, Katherine HLTH:EX  
**Cc:** Lindy McIntyre; Rick Trifunov; Andrew Little  
**Subject:** RE: PPPs purchased in CDN \$

Hello Wendy,

Lindy forwarded your request and asked that I respond. The following product are purchased in CDN \$\$, all the others are in US \$\$.

Kogenate/Kovaltry  
Alprolix  
Eloctate  
WinRho/HepaGam B/VariZIG  
NiaStase  
Tretten  
Benefix  
Xyntha  
Cinryze

Hope this helps,  
Peter

---

Peter Saunders - Associate Director, National Operations (W) 613-739-2327 (C) 613-298-2965

Blood. It's in you to give.  
Call 1-888-2 DONATE to book an appointment.

---

**From:** Vowles, Wendy M HLTH:EX [<mailto:Wendy.Vowles@gov.bc.ca>]  
**Sent:** 2016-09-20 1:23 PM  
**To:** Lindy McIntyre  
**Cc:** Leong, Katherine HLTH:EX  
**Subject:** PPPs purchased in CDN \$

Hi Lindy,

Just updating some stuff and want to confirm the products purchased in CDN \$. I have noted Benefix, rFVIIa, rFIX. Is that the complete list? I have a note about fibrinogen but not sure... is this purchased in US\$?

Not urgent.

Thanks,

Wendy Vowles  
Director, Blood Services  
Laboratory, Diagnostic and Blood Services Branch  
Ministry of Health  
phone: **250 356-1721**  
fax: 250 356-1679

*This email is intended only for the use of the individual or organization to whom it is addressed. It may contain information that is privileged or confidential. Any distribution, disclosure, copying, or other use by anyone else is strictly prohibited. If you have received this in error, please telephone or e-mail the sender immediately and delete the message.*



**From:** Ishneet Singh  
**To:** [jstoffman@cancercare.mb.ca](mailto:jstoffman@cancercare.mb.ca); [David Page \(dpage@hemophilia.ca\)](mailto:dpage@hemophilia.ca); [CBS HLS Reps; Supply Chain Leadership Team; supply chain ops planners; Medical Officers; wendy.peppel@gov.mb.ca; Shelley.Stopera@gov.mb.ca; muirhead@mymts.net; Robert.Coupland@interiorhealth.ca; doug.morrison@fraserhealth.ca; atinmouth@ottawahospital.on.ca; Debra Lane; Irene Sadek; infesser@ihis.org; pavenskik@smh.ca; Kathryn Webert; lakshmi.rajappannair@horizonNB.ca; meer-taher shabani-rad; Susan Nahirniak; Ted Alport; Lindy McIntyre; lucinda.whitman@easternhealth.ca; Lucinda.whitman@mun.ca; Rick Trifunov; vincent.laroche.cha@ssss.gouv.qc.ca; Donna.Ledingham@rqhealth.ca; Sudeep.Shivakumar@cdha.nshealth.ca; Peter Saunders; Angela Carpenter; XT:Bertelsen, Brian HLTH:IN; Kimberly Riles; Kirstin Nucklaus; Mr. Dai Kim; Mr. Dave Dell; Mr. Patrick O'Byrne; Ms. Daphne Osborne; Ms. Glenna Laing; Ms. Judy Hoff; Ms. Marina Hamilton; Ms. Sonia Marchand; XT:HLTH Van Hees, Violet; Vowles, Wendy M HLTH:EX](#)  
**Subject:** Recombinant Factor RFP 442-2015 Results Communication  
**Date:** Wednesday, April 6, 2016 12:58:48 PM  
**Attachments:** [image002.png](#)  
[RFP 442-15 Results Communication.pdf](#)

---

Good day!

Canadian Blood Services is very pleased to announce the results of its recent Recombinant Factor VIII and IX tender, the benefits to be realized to the patient community, and the safe and secure supply of both product categories that will be maintained. These changes once fully implemented will also generate significant savings for these products. Further information about the planned patient switches required to support our decisions are also provided.

Further information, including a Q&A document, will follow via a formal announcement through our usual Customer Letter process which will also be posted to our website in both official languages.

Sincerely,

Ishneet Singh on behalf of Rick Trifunov

Rick Trifunov

Director, Supply Chain Operations Planning

Office: 613.739.2583

Ishneet Singh

Senior Administrative Assistant

Supply Chain Operations Planning

Office: 613.739.2523

give life



## **Canadian Blood Services Recombinant Factor VIII and Recombinant Factor IX Contracts and Contract Awards**

Canadian Blood Services is very pleased to announce the results of its recent Recombinant Factor VIII and IX tender, the benefits to be realized to the patient community, and the safe and secure supply of both product categories that will be maintained. These changes once fully implemented will also generate significant savings for these products. Further information about the planned patient switches required to support our decisions are also provided.

The recommendations for the award, execution and delivery of two-year contracts (with renewal options) for Recombinant Factor VIII and Recombinant Factor IX products have been approved by Canadian Blood Services and its Board of Directors as follows:

- a. To Pfizer: Approximately 40 million IUs annually of standard acting rFIX amounts for the “BeneFIX” product and approximately 95 million IUs annually of standard acting rFVIII for the “Xyntha” product.
- b. To Octapharma: No more than approximately 5 million IUs annually of standard acting rFVIII for the “Nuwiq” product.
- c. To Bayer: Continuation of existing rFVIII product amounts for the “Kogenate” and moving to “Kovaltry” products with a minimum total of 90 million IUs annually.

These recommendations coming out of the recent Canadian Blood Services Request for Proposals (RFP) for recombinant factor VIII and IX replacement therapy have resulted in the need to transition patients with factor VIII deficiency from Advate, which will no longer be available after the current inventory on hand is depleted. The majority of the Advate market share has been awarded to Xyntha, and the expectation is that Advate patients will be transitioned to Xyntha over the spring and summer months. A quantity of Nuwiq will be obtained as well, for patient benefit as this product shows potential benefits and lower inhibitor rates for previously untreated patients and other patients in the opinion of the treating team. Patients on Kogenate FS should not be required to switch recombinant molecules, although they will be transitioned to the new Bayer brand, Kovaltry, which is replacing Kogenate FS in the coming months.

Benefix will continue to be the principal recombinant factor IX product.

The extended half-life products, Eloctate for factor VIII and Alprolix for factor IX, were not specifically part of the RFP, but both are currently available for patients currently using standard half-life products who might benefit from transitioning to these products, with contracts that extend to March 31, 2017 (with renewal option).

The RFP selection committee was comprised of representatives of Canadian Blood Services, Association of Hemophilia Clinic Directors of Canada (AHCDC), Canadian Association of Nurses in Hemophilia Care (CANHC), and Canadian Hemophilia Society (CHS), and the input of the physicians, nurses, and patients was carefully considered during the evaluation process. The impact of transitioning was central to the

discussions and the final recommendations. The recommendation of a major product change for almost half of the hemophilia A population took into account the safety, efficacy, and convenience of the products, as well as the potential for considerable cost savings for the Canadian health care system. The entire committee was supportive of the final outcome.

Logistical planning to support the national product transitions is currently underway at Canadian Blood Services, and will be discussed with the treatment centres prior to initiation. Cooperation between the vendors, Canadian Blood Services and the clinics will be paramount for a successful transition. It is anticipated that each clinic will need to determine how best to manage the transition within the context of its program and the resources available. The use of CBDR/MyCBDR or an equivalent home infusion reporting system during the transition period will be beneficial for both patient care and inventory management.

Any questions relating to the RFP itself should be directed to Canadian Blood Services Procurement department, Richard Lough Manager Procurement at [Richard.Lough@blood.ca](mailto:Richard.Lough@blood.ca). All other questions please contact Rick Trifunov ([Rick.Trifunov@blood.ca](mailto:Rick.Trifunov@blood.ca)) and/or Peter Saunders ([Peter.Saunders@blood.ca](mailto:Peter.Saunders@blood.ca)).

Page 238 to/à Page 239

Withheld pursuant to/removed as

Copyright